相关实验视频
Updated: Jun 6, 2025

06:51
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
5.3K
遗传性出血端膜切除症:一个以儿科为重点的综述
Chelsey Ortman1, Elissa Ortolani2
1Department of Pediatric Neurosciences, Ascension Dell Children's Medical Center, University of Texas at Austin, United States.
Seminars in pediatric neurology
|December 2, 2024
概括
遗传性出血端膜切除症 (HHT) 会导致危险的血管形和出血. 目前的管理重点是治疗并发症,因为对HHT的治疗仍然难以捉摸.
科学领域:
- 血管医学 血管医学
- 遗传学 是一个遗传学.
- 临床表现 临床表现
背景情况:
- 遗传性出血端膜病 (HHT) 是一种遗传性疾病,其特征是血管形.
- 这些形可以影响各种器官,包括皮肤,鼻子粘膜,胃肠道,肺部,肝脏和中枢神经系统.
- 并发症包括显著的出血,贫血,以及由动脉静脉转移引起的问题.
研究的目的:
- 概述HHT的临床表现.
- 描述诊断标准和遗传基础.
- 审查目前对与HHT相关的血管并发症的管理策略.
主要方法:
- 对HHT的临床表现和诊断标准的审查.
- 与HHT相关的遗传变异的总结.
- 目前医疗和干预治疗选择的概述.
主要成果:
- HHT呈现出各种各样的血管形,从telangiectasias到动脉静脉形.
- 诊断依赖于库拉索的标准,基因测试可以识别ENG,ACVRL1或SMAD4基因的变异.
- 管理涉及药物,如特兰胺酸和贝瓦齐祖马布,在适当的情况下,与内血管或手术干预一起.
结论:
- HHT是一种复杂的疾病,由于血管形,具有显著的出血风险.
- 虽然已经确定了遗传因素,但尚未找到确定的治疗方法.
- 目前的治疗方法旨在有效地管理症状并预防并发症.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
46
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
46
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141

